Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (51-60 of 468) with videos related to

Pageof 47
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Development of effective new treatments for multiple myelomaKenneth C Anderson, Richard Pazdur, Ann T Farrell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|December 9, 2024
Autopsy of a Drug Withdrawal - The Case of Melphalan FlufenamideBindu Kanapuru, Theresa Carioti, Nicole Gormley, et al.
The Oncologist|October 29, 2002
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug statusMartin H Cohen, Marie L Moses, Richard Pazdur
JAMA Oncology|July 15, 2021
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug DevelopmentLola Fashoyin-Aje, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|June 28, 2018
Metastasis-free Survival - A New End Point in Prostate Cancer TrialsJulia A Beaver, Paul G Kluetz, Richard Pazdur
The Oncologist|February 29, 2008
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemiaSuzanne Demko, Jeffrey Summers, Patricia Keegan, et al.
Clinical Pharmacology and Therapeutics|July 13, 2020
FDA Oncology Center of Excellence Review Processes and ToolsJennifer J Gao, Paul G Kluetz, Richard Pazdur
JAMA Oncology|March 25, 2021
The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-makingDonna Przepiorka, R Angelo de Claro, Richard Pazdur
Pageof 47

Showing results (51-60 of 468) with videos related to

Sort By:
Pageof 47
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Development of effective new treatments for multiple myelomaKenneth C Anderson, Richard Pazdur, Ann T Farrell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiformeMartin H Cohen, John R Johnson, Richard Pazdur
The New England Journal of Medicine|February 15, 2019
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast CancerTatiana M Prowell, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|December 9, 2024
Autopsy of a Drug Withdrawal - The Case of Melphalan FlufenamideBindu Kanapuru, Theresa Carioti, Nicole Gormley, et al.
The Oncologist|October 29, 2002
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug statusMartin H Cohen, Marie L Moses, Richard Pazdur
JAMA Oncology|July 15, 2021
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug DevelopmentLola Fashoyin-Aje, Julia A Beaver, Richard Pazdur
The New England Journal of Medicine|June 28, 2018
Metastasis-free Survival - A New End Point in Prostate Cancer TrialsJulia A Beaver, Paul G Kluetz, Richard Pazdur
The Oncologist|February 29, 2008
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemiaSuzanne Demko, Jeffrey Summers, Patricia Keegan, et al.
Clinical Pharmacology and Therapeutics|July 13, 2020
FDA Oncology Center of Excellence Review Processes and ToolsJennifer J Gao, Paul G Kluetz, Richard Pazdur
JAMA Oncology|March 25, 2021
The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-makingDonna Przepiorka, R Angelo de Claro, Richard Pazdur
Pageof 47